Spyre Therapeutics, Inc. 8-K

What Happened

• Spyre Therapeutics, Inc. filed a Current Report on Form 8-K on January 12, 2026, disclosing a press release and an updated corporate presentation posted to its website.
• The materials provide updates on the company’s ongoing clinical trials and announce the appointment of Kate Tansey Chevlen as Chief Commercial Officer. The press release and presentation are attached to the 8-K as Exhibits 99.1 and 99.2.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 7.01 Reg FD disclosure).
• Documents posted: press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2).
• Executive change: Kate Tansey Chevlen named Chief Commercial Officer (appointment announced in the materials).
• Subject matter: updates on the company’s ongoing clinical trials (details in the attached press release and presentation).

Why It Matters

• Investors should note the management change at the commercial leadership level, which may affect future go-to-market strategy as Spyre advances clinical programs.
• The posted presentation and press release are the company’s official, contemporaneous disclosures on trial progress and leadership — investors seeking specific trial timelines, data milestones or commercialization plans should review Exhibits 99.1 and 99.2 for full details.